MX2020008258A - Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. - Google Patents

Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.

Info

Publication number
MX2020008258A
MX2020008258A MX2020008258A MX2020008258A MX2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A
Authority
MX
Mexico
Prior art keywords
pediatric
treatment methods
niraparib
niraparib formulations
formulations
Prior art date
Application number
MX2020008258A
Other languages
English (en)
Inventor
Clare Medendorp
John Chaber
Simon Mcgurk
David Lust
Kevin Johnston
Duantel Verwijs
Aaron Nelson
Melanie Ronsheim
Steve Ruddy
Katie Poutsiaka
Hoorn Danny Van
Aileen Dowling
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MX2020008258A publication Critical patent/MX2020008258A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere a métodos para tratar el cáncer en sujetos pediátricos que comprenden la administración del compuesto de niraparib en una forma de dosificación oral adecuada y, opcionalmente, en combinación con un segundo agente terapéutico, tal como un inhibidor de PD-1.
MX2020008258A 2018-02-05 2019-02-05 Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. MX2020008258A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626644P 2018-02-05 2018-02-05
US201862626646P 2018-02-05 2018-02-05
PCT/US2019/016648 WO2019152989A1 (en) 2018-02-05 2019-02-05 Pediatric niraparib formulations and pediatric treatment methods

Publications (1)

Publication Number Publication Date
MX2020008258A true MX2020008258A (es) 2020-11-13

Family

ID=65494567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008258A MX2020008258A (es) 2018-02-05 2019-02-05 Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.

Country Status (14)

Country Link
US (1) US20210030735A1 (es)
EP (1) EP3749352A1 (es)
JP (1) JP2021513524A (es)
KR (1) KR20200118117A (es)
CN (1) CN111918667A (es)
AU (1) AU2019215450A1 (es)
BR (1) BR112020015909A2 (es)
CA (1) CA3090479A1 (es)
IL (1) IL276494A (es)
MX (1) MX2020008258A (es)
RU (1) RU2020129236A (es)
SG (1) SG11202007420PA (es)
TW (1) TW201944999A (es)
WO (1) WO2019152989A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
EP3624850A1 (en) 2017-05-18 2020-03-25 Tesaro, Inc. Combination therapies for treating cancer
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
KR20200086664A (ko) 2017-09-30 2020-07-17 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
CN111093706B (zh) * 2017-12-06 2022-06-21 江苏恒瑞医药股份有限公司 Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
WO2021136523A1 (zh) * 2019-12-31 2021-07-08 甫康（上海）健康科技有限责任公司 一种用于治疗肿瘤的药物组合及其应用
US20230181532A1 (en) * 2020-05-18 2023-06-15 Board Of Regents, The University Of Texas System Granules for 3d printing technology
KR20240093836A (ko) * 2021-11-10 2024-06-24 크리티테크, 인크. 니라파립 입자 및 이의 용도
US20230201122A1 (en) * 2021-12-23 2023-06-29 Boston Scientific Medical Device Limited Chemoembolic compositions and methods of treatment using them
US20250352534A1 (en) * 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
EP4712976A1 (en) * 2023-05-17 2026-03-25 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
AU2024362581A1 (en) * 2023-10-19 2026-04-30 Tesaro, Inc. Methods of treating cancer with anti-pd-1 agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606337D0 (en) 1996-03-26 1996-05-29 Freeman Reginald E Rheometer
US7997103B2 (en) * 2002-12-10 2011-08-16 Lg Electronics Inc. Tub having structurally strengthened rear wall and washing machine with the same therein
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
SG190006A1 (en) * 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
US20150283083A1 (en) * 2012-11-19 2015-10-08 Azanta A/S Dispersible Tablet
MX2015007185A (es) * 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
CN106458885B (zh) * 2013-10-25 2019-12-10 生命技术公司 用于聚合酶链式反应系统的新颖化合物及其应用
EP3148336B1 (en) * 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
KR20180004740A (ko) * 2015-04-20 2018-01-12 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
US10660954B2 (en) * 2015-07-31 2020-05-26 University Of Florida Research Foundation, Incorporated Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
CA3005730A1 (en) * 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
CA2916970A1 (en) * 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
WO2017210608A1 (en) * 2016-06-02 2017-12-07 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
FI3478286T3 (fi) * 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
BR112019020191A2 (pt) 2017-03-27 2020-04-22 Tesaro Inc formulações de niraparib
EA201992177A1 (ru) 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
EP3624850A1 (en) * 2017-05-18 2020-03-25 Tesaro, Inc. Combination therapies for treating cancer

Also Published As

Publication number Publication date
CN111918667A (zh) 2020-11-10
TW201944999A (zh) 2019-12-01
KR20200118117A (ko) 2020-10-14
SG11202007420PA (en) 2020-09-29
US20210030735A1 (en) 2021-02-04
RU2020129236A (ru) 2022-03-09
IL276494A (en) 2020-09-30
CA3090479A1 (en) 2019-08-08
JP2021513524A (ja) 2021-05-27
WO2019152989A1 (en) 2019-08-08
AU2019215450A1 (en) 2020-08-27
BR112020015909A2 (pt) 2020-12-15
EP3749352A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12016502352A1 (en) Pharmaceutical composition
HK1247850A1 (zh) Pd-1 拮抗剂与egfr 抑制剂的组合
TW201613578A (en) Pharmaceutical combinations
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
JOP20200015A1 (ar) توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
WO2015035410A8 (en) Cancer therapy
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
MX2019011749A (es) Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia.
WO2019222130A8 (en) Combination treatment with antibody-drug conjugates and flt3 inhibitors